PFE - Competitor Analysis: Evaluating Pfizer And Competitors In Pharmaceuticals Industry | Benzinga
In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating Pfizer (NYSE:PFE) in relation to its major competitors in the Pharmaceuticals industry. By closely examining crucial financial metrics, market position, and growth prospects, we aim to offer valuable insights for investors and shed light on company's performance within the industry.
Pfizer Background
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| Pfizer Inc | |||||||
| 15.45 | |||||||
| 1.65 | |||||||
| 2.36 | |||||||
| -2.43% | |||||||
| $-1.1 | |||||||
| $3.96 | |||||||
| -41.55% | |||||||
| Eli Lilly and Co | |||||||
| 113.87 | |||||||
| 53.18 | |||||||
| 17.71 | |||||||
| -0.52% | |||||||
| $0.96 | |||||||
| $7.64 | |||||||
| 36.84% | |||||||
| Novo Nordisk A/S | |||||||
| 43.85 | |||||||
| 35.14 | |||||||
| 15.41 | |||||||
| 24.5% | |||||||
| $32.76 | |||||||
| $49.02 | |||||||
| 28.89% | |||||||
| Johnson & Johnson | |||||||
| 30.33 | |||||||
| 5.46 | |||||||
| 4.29 | |||||||
| 35.56% | |||||||
| $7.24 | |||||||
| $14.74 | |||||||
| 6.78% | |||||||
| Merck & Co Inc | |||||||
| 66.05 | |||||||
| 7.30 | |||||||
| 5.11 | |||||||
| 11.87% | |||||||
| $6.95 | |||||||
| $11.7 | |||||||
| 6.71% | |||||||
| Novartis AG | |||||||
| 28.04 | |||||||
| 5.83 | |||||||
| 4.22 | |||||||
| 3.91% | |||||||
| $4.88 | |||||||
| $8.97 | |||||||
| 12.14% | |||||||
| AstraZeneca PLC | |||||||
| 35.21 | |||||||
| 5.55 | |||||||
| 4.61 | |||||||
| 3.68% | |||||||
| $3.33 | |||||||
| $9.4 | |||||||
| 4.64% | |||||||
| Bristol-Myers Squibb Co | |||||||
| 12.72 | |||||||
| 3.52 | |||||||
| 2.34 | |||||||
| 6.32% | |||||||
| $4.85 | |||||||
| $8.46 | |||||||
| -2.25% | |||||||
| Zoetis Inc | |||||||
| 38.37 | |||||||
| 17.03 | |||||||
| 10.44 | |||||||
| 12.28% | |||||||
| $0.9 | |||||||
| $1.51 | |||||||
| 7.44% | |||||||
| GSK PLC | |||||||
| 10.54 | |||||||
| 4.89 | |||||||
| 2.16 | |||||||
| 11.34% | |||||||
| $2.55 | |||||||
| $5.88 | |||||||
| 4.06% | |||||||
| Takeda Pharmaceutical Co Ltd | |||||||
| 35.92 | |||||||
| 0.97 | |||||||
| 1.65 | |||||||
| -0.69% | |||||||
| $202.28 | |||||||
| $699.51 | |||||||
| 4.07% | |||||||
| Viatris Inc | |||||||
| 7.55 | |||||||
| 0.66 | |||||||
| 0.89 | |||||||
| 1.59% | |||||||
| $1.22 | |||||||
| $1.69 | |||||||
| -3.34% | |||||||
| Dr Reddy's Laboratories Ltd | |||||||
| 18.48 | |||||||
| 3.71 | |||||||
| 3.52 | |||||||
| 5.94% | |||||||
| $23.28 | |||||||
| $40.37 | |||||||
| 9.11% | |||||||
| Jazz Pharmaceuticals PLC | |||||||
| 140.39 | |||||||
| 2.10 | |||||||
| 2.14 | |||||||
| 4.19% | |||||||
| $0.33 | |||||||
| $0.87 | |||||||
| 3.35% | |||||||
| Amphastar Pharmaceuticals Inc | |||||||
| 21.50 | |||||||
| 4.43 | |||||||
| 4.82 | |||||||
| 8.31% | |||||||
| $0.09 | |||||||
| $0.11 | |||||||
| 50.3% | |||||||
| Corcept Therapeutics Inc | |||||||
| 30.52 | |||||||
| 5.45 | |||||||
| 6.14 | |||||||
| 7.06% | |||||||
| $0.03 | |||||||
| $0.12 | |||||||
| 21.5% | |||||||
| Average | |||||||
| 42.22 | |||||||
| 10.35 | |||||||
| 5.7 | |||||||
| 9.02% | |||||||
| $19.44 | |||||||
| $57.33 | |||||||
| 12.68% |